Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
TiumBio Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06025552CT.gov Study of TU7710 in Warfarin Anti-coagulated Healthy Male Subjects | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Blood Coagulation Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| tu7710 (this asset) | TiumBio Co., Ltd. | P1 | CC · 47 |
| Kcentra | CSL Behring | P3 | BB |
| Factor Ix | National Heart, Lung, and Blood Institute (NHLBI) | P3 | BB |
| Beriplex® P/N | CSL Behring | P3 | BB |
| Rifaximin | University of Roma La Sapienza | P4 | B |
| Fresh Frozen Plasma | CSL Behring | P3 | B |
| Edoxaban | Samsung Medical Center | P2/3 | B |
| Enoxaparin | Samsung Medical Center | P2/3 | B |
| Spk-8016 | Spark Therapeutics, Inc. | P1/2 | CCC |
+2 more in the Blood Coagulation Disease cohort
Other indications for tu7710
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hemophilia B | — | P1 | CC · 44 |
| Hemophilia A | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. tu7710 in Blood Coagulation Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tu7710-blood-coagulation-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →